Fortress Biotech (FBIO) News Today → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free FBIO Stock Alerts $1.75 -0.03 (-1.69%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineJourney Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024globenewswire.com - May 7 at 8:30 AMJourney Medical Corporation Appoints Joseph Benesch as Chief Financial Officerglobenewswire.com - May 1 at 4:01 PMJourney Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024globenewswire.com - April 25 at 8:30 AM3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024investorplace.com - April 11 at 12:24 PMFortress Biotech, Inc.: Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlightsfinanznachrichten.de - March 29 at 8:18 AMFortress Biotech Reports 2023 Financial Results and Recent Corporate Highlightsglobenewswire.com - March 28 at 4:05 PMMustang Bio, Inc.: Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseasesfinanznachrichten.de - March 28 at 12:10 PMMustang Bio stock climbs 9% amid drug development updatemsn.com - March 28 at 12:10 PMCheckpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlightsglobenewswire.com - March 22 at 8:30 AMJourney Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlightsglobenewswire.com - March 21 at 4:01 PMAvenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlightsfinance.yahoo.com - March 18 at 4:11 PMJourney Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosaceaglobenewswire.com - March 18 at 8:30 AMJourney Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024globenewswire.com - March 15 at 8:30 AMJourney Medical Corporation to Participate in the 36th Annual ROTH Conferenceglobenewswire.com - March 13 at 8:30 AMFortress Biotech to Participate in 36th Annual ROTH Conferenceglobenewswire.com - March 12 at 8:30 AMJourney Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meetingglobenewswire.com - March 11 at 8:30 AMFortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Diseaseglobenewswire.com - March 4 at 8:30 AMCheckpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Marketfinance.yahoo.com - January 29 at 8:44 AMAvenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conferencefinance.yahoo.com - January 11 at 8:22 AMInsider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires 50,000 ...finance.yahoo.com - January 9 at 6:05 PMJourney Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosaceafinance.yahoo.com - January 5 at 9:26 AMAvenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceedsfinance.yahoo.com - January 5 at 9:26 AMAvenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadolfinance.yahoo.com - January 4 at 9:10 AMAvenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)finance.yahoo.com - January 2 at 9:00 AMWhy Fortress Biotech Shares Are Tumbling Todaymarkets.businessinsider.com - December 29 at 11:50 AMMustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meetingfinance.yahoo.com - December 11 at 9:22 AMJourney Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosaceafinance.yahoo.com - December 6 at 9:07 AMSentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeuticsfinance.yahoo.com - December 6 at 9:07 AMCyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.finance.yahoo.com - December 6 at 9:07 AMFortress Biotech Stock (NASDAQ:FBIO), Analyst Ratings, Price Targets, Predictionsbenzinga.com - December 1 at 3:00 PMAvenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meetingfinance.yahoo.com - December 1 at 9:59 AMRoth MKM Maintains Buy Rating for Fortress Biotech: Here's What You Need To Knowmarkets.businessinsider.com - November 29 at 2:13 PMThinking about buying stock in Coinbase Global, Celsius Holdings, Cadence Design Systems, Coherus Biosciences, or Fortress Biotech?benzinga.com - November 17 at 9:57 AMCheckpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlightsfinance.yahoo.com - November 13 at 7:31 PMFortress Biotech Shares Fall Premarket on Public Offering Plansmarketwatch.com - November 10 at 8:13 AMMustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - October 26 at 1:34 PMJourney Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)finance.yahoo.com - October 20 at 9:04 AMCheckpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancerfinance.yahoo.com - October 18 at 8:52 AMFortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1finance.yahoo.com - October 16 at 9:41 AMFortress Biotech Inc. 9.375% Cum. Pfd. Series Awsj.com - September 22 at 6:25 PMFortress Biotech, Inc. 9.375% CUM RED PER PREF SER A USD25.00 goes ex-dividend tomorrowseekingalpha.com - September 13 at 3:50 PMMustang Bio to Participate in Upcoming September 2023 Investor Conferencesfinance.yahoo.com - September 7 at 8:46 AMFortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 7 at 8:46 AMJourney Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nationsfinance.yahoo.com - September 6 at 8:51 AMMustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapyfinance.yahoo.com - August 16 at 10:12 AMFortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlightsfinanznachrichten.de - August 15 at 7:23 AMFortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlightsfinance.yahoo.com - August 14 at 4:21 PMMustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlightsfinance.yahoo.com - August 14 at 4:21 PMJourney Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlightsfinance.yahoo.com - August 8 at 4:09 PMMustang Bio to Participate in Two August 2023 Investor Conferencesfinance.yahoo.com - August 3 at 8:33 AM Get Fortress Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. FBIO Media Mentions By Week FBIO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FBIO News Sentiment▼0.000.36▲Average Medical News Sentiment FBIO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FBIO Articles This Week▼11▲FBIO Articles Average Week Get Fortress Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BOLT News MTEM News CMRX News EBS News VIRX News THTX News JAN News IPA News ENLV News DARE News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FBIO) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm Press348 million Americans lives to END as we know it?The Oxford ClubThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
